BiotechTube

HSK21542 Injection + Tramadol hydrochloride + placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postoperative Analgesia

Conditions

Postoperative Analgesia

Trial Timeline

Jun 8, 2022 → Mar 28, 2023

NCT ID
NCT05390905

About HSK21542 Injection + Tramadol hydrochloride + placebo

HSK21542 Injection + Tramadol hydrochloride + placebo is a phase 3 stage product being developed by Haisco Pharmaceutical Group for Postoperative Analgesia. The current trial status is completed. This product is registered under clinical trial identifier NCT05390905. Target conditions include Postoperative Analgesia.

What happened to similar drugs?

20 of 20 similar drugs in Postoperative Analgesia were approved

Approved (20) Terminated (3) Active (0)
✅Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
✅EsomeprazoleAstraZenecaApproved
✅Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
✅Sugammadex + NeostigmineMerckApproved
✅Aprepitant + Dexamethasone + Ondansetron + DexamethasoneMerckApproved
✅Suvorexant + PlaceboMerckApproved
✅Aprepitant plus Ondansetron + Ondansetron plus placeboMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05390905Phase 3Completed

Competing Products

20 competing products in Postoperative Analgesia

See all competitors
ProductCompanyStageHype Score
Naldemedine + PlaceboShionogiPhase 2
27
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVEisaiApproved
43
Lemborexant 5 mg + Control (placebo) groupEisaiPhase 2
42
Ondansetron + PalonosetronEisaiPhase 2
35
AQUAVAN (fospropofol disodium; GPI 15715 )EisaiPhase 2
35
ONO-1101Ono PharmaceuticalPhase 2
35
ONO-1101Ono PharmaceuticalPhase 2/3
38
Levofloxacin Ophthalmic + CefuroximeSanten PharmaceuticalPhase 1/2
28
Levofloxacin Ophthalmic Product + Moxifloxacin Ophthalmic SolutionSanten PharmaceuticalPhase 1/2
28
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
29
SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
36
SHR8554 InjectionJiangsu Hengrui MedicinePhase 1
29
EsomeprazoleAstraZenecaApproved
43
deep neuromuscular blockMerckPre-clinical
26
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + PlaceboMerckPhase 2
35
MK0966, rofecoxib + Comparator: valdecoxibMerckPhase 3
40
Aprepitant, Dexamethasone, Ondansetron + Aprepitant, Dexamethasone, PlaceboMerckApproved
43
MK0719MerckPhase 2
27
Sugammadex + NeostigmineMerckApproved
43
MK0869, aprepitant + Comparator: ondansetron IVMerckPhase 3
40